Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention
Frontiers in Integrative Neuroscience · 17.02.2022 · 16
DOI: 10.3389/fnint.2022.765324 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Integrative Neuroscience, online erschienen am 17.02.2022. Verfasst von Lívea Dornela Godoy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 361 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Parvalbumin is a calcium-binding protein present in inhibitory interneurons that play an essential role in regulating many physiological processes, such as intracellular signaling and synaptic transmission. Changes in parvalbumin expression are deeply related to epilepsy, which is considered one of the most disabling neuropathologies. Epilepsy is a complex multi-factor group of disorders characterized by periods of hypersynchronous activity and hyperexcitability within brain networks. In this scenario, inhibitory neurotransmission dysfunction in modulating excitatory transmission related to the loss of subsets of parvalbumin-expressing inhibitory interneuron may have a prominent role in disrupted excitability. Some studies also reported that parvalbumin-positive interneurons altered function might contribute to psychiatric comorbidities associated with epilepsy, such as depression, anxiety, and psychosis. Understanding the epileptogenic process and comorbidities associated with epilepsy have significantly advanced through preclinical and clinical investigation. In this review, evidence from parvalbumin altered function in epilepsy and associated psychiatric comorbidities were explored with a translational perspective. Some advances in potential therapeutic interventions are highlighted, from current antiepileptic and neuroprotective drugs to cutting edge modulation of parvalbumin subpopulations using optogenetics, designer receptors exclusively activated by designer drugs (DREADD) techniques, transcranial magnetic stimulation, genome engineering, and cell grafting. Creating new perspectives on mechanisms and therapeutic strategies is valuable for understanding the pathophysiology of epilepsy and its psychiatric comorbidities and improving efficiency in clinical intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
- Department of Neuroscience and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Godoy, L. D., Prizon, T., Rossignoli, M. T., Leite, J. P., & Liberato, J. L. (2022). Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention. Frontiers in Integrative Neuroscience, 16. https://doi.org/10.3389/fnint.2022.765324
Vancouver
Godoy LD, Prizon T, Rossignoli MT, Leite JP, Liberato JL. Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention. Frontiers in Integrative Neuroscience. 2022;16. doi:10.3389/fnint.2022.765324
BibTeX
@article{Godoy2022,
author = {Godoy, Lívea Dornela and Prizon, Tamiris and Rossignoli, Matheus Teixeira and Leite, João Pereira and Liberato, José Luiz},
title = {Parvalbumin Role in Epilepsy and Psychiatric Comorbidities: From Mechanism to Intervention},
journal = {Frontiers in Integrative Neuroscience},
year = {2022},
volume = {16},
doi = {10.3389/fnint.2022.765324}
}
EUVIMED